India is the only major country globally that is asking its citizens to pay for getting vaccinated against Covid-19. But if having a majority of citizens in a developing country of 1.3 billion paying out of their meager incomes to literally stay alive is bad, then imagine the consequences of allowing virtually unrestricted pricing by private players.

The current formula devised by the Indian federal government splits all available vaccines between itself, state governments, and private players in a ratio of 50:25:25.

It’s the 25% vaccines that are being sold and administered by private hospitals and players where there’s both tremendous opacity and variance.

If you are in India, and got vaccinated after 1st May, between the age of 18-44, and received your dose through a private channel like a hospital, your apartment complex RWA, or via your employer, this survey is for you.

For the purpose of simplicity, let’s talk only about one vaccine – Covishield. This is the Indian brand name of the Astra Zeneca vaccine licensed, manufactured, and sold by Serum Institute of India (SII), the world’s largest vaccine maker. It is also the one currently being manufactured at the largest volumes in India, compared to Covaxin (developed and manufactured by Bharat Biotech) and Russia’s Sputnik (currently only being imported).

The price at which Covishield is sold by SII to private hospitals or players is Rs 600 per dose. Which, including taxes and transportation, comes to around Rs 650.

Once hospitals or procurers add in their own costs and profit margins, that ends up costing Indians anywhere from Rs 850 to Rs 1800.

Not only is that a huge variation, it is also largely opaque. Prices are fixed between hospitals and bulk buyers like companies (who want to vaccinate their employees) or resident welfare associations (who want to vaccinate residents in their communities).

Through this survey, The Ken hopes to shine some much-needed light on the sources, prices, and methods prevalent in the private sector vaccination space. We hope to be guided in our journalism by the data that is thrown up, and the questions it forces us to reckon with.

This survey, like all our subscriber-only surveys, is respectful of your privacy. As a business, we do not run advertising or allow sponsorships. Thus, we have never and will never use subscriber data or responses for advertising or tracking purposes. 

Furthermore, we commit to deleting all survey responses from all our systems within the next 30 days. That will allow us to retain only the aggregate results while deleting individual responses.

Please consider taking this survey if you’re in India. If you aren’t vaccinated yet, you can tell us about the prices paid by any of your family members. 

AUTHOR

Team Ken

The Ken is a new, digital, subscription-driven publication headquartered out of Bangalore, India. Founded by a team of experienced journalists and entrepreneurs, The Ken’s goal is to deliver fresh and original business insight through well-narrated stories to professionals, entrepreneurs, investors and leaders every morning.

View Full Profile

Available exclusively to subscribers of The Ken India

This story is a part of The Ken India edition. Subscribe. Questions?

MOST POPULAR

Annual Subscription

12-month access to 200+ stories, archive of 800+ stories from our India edition. Plus our premium newsletters, Beyond The First Order and The Nutgraf worth Rs. 99/month or $2/month each for free.

Rs. 2,750

Subscribe
 

Quarterly Subscription

3-month access to 60+ new stories with 3-months worth of archives from our India edition. Plus our premium newsletters, Beyond The First Order and The Nutgraf worth Rs. 99/month or $2/month each for free.

Rs. 1,750

Subscribe
 

Single Story

Instant access to this story for a year along with comment privileges.

Rs. 500

Subscribe
MOST POPULAR

Annual Subscription

12-month access to 150+ stories from Southeast Asia.

$ 120

Subscribe
 

Quarterly Subscription

3-month access to 35+ stories from Southeast Asia.

$ 50

Subscribe
 

Single Story

Instant access to this story for a year along with comment privileges.

$ 20

Subscribe

Questions?

What is The Ken?

The Ken is a subscription-only business journalism website and app that provides coverage across two editions - India and Southeast Asia.

What kind of stories do you write?

We publish sharp, original and reported stories on technology, business and healthcare. Our stories are forward-looking, analytical and directional — supported by data, visualisations and infographics.

We use language and narrative that is accessible to even lay readers. And we optimise for quality over quantity, every single time.

What do I get if I subscribe?

For subscribers of the India edition, we publish a new story every weekday, a premium daily newsletter, Beyond The First Order and a weekly newsletter - The Nutgraf.

For subscribers of the Southeast Asia edition, we publish a new story three days a week and a weekly newsletter, Strait Up.

The annual subscription will get you complete, exclusive access to our archive of previously published stories for your edition, along with access to our subscriber-only mobile apps, our premium comment sections, our newsletter archives and several other gifts and benefits.

Do I need to pay separately for your premium newsletters?

Nope. Paid, premium subscribers of The Ken get our newsletters delivered for free.

Does a subscription to the India edition grant me access to Southeast Asia stories? Or vice-versa?

Afraid not. Each edition is separate with its own subscription plan. The India edition publishes stories focused on India. The Southeast Asia edition is focused on Southeast Asia. We may occasionally cross-publish stories from one edition to the other.

Do you offer an all-access joint subscription for both editions?

Not yet. If you’d like to access both editions, you’ll have to purchase two subscriptions separately - one for India and the other for Southeast Asia.

Do you offer any discounts?

No. We have a zero discounts policy.

Is there a free trial I can opt for?

We don’t offer any trials, but you can sign up for a free account which will give you access to the weekly free story, our archive of free stories and summaries of the paid stories. You can stay on the free account as long as you’d like.

Do you offer refunds?

We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am facing some trouble purchasing a subscription. What can I do?

Please write to us at support@the-ken.com detailing the error or queries.